Axon Enterprise (NASDAQ:AXON) Now Covered by TD Cowen

TD Cowen started coverage on shares of Axon Enterprise (NASDAQ:AXON) in a research note published on Wednesday, Marketbeat reports. The brokerage issued a buy rating and a $700.00 price target on the biotechnology company’s stock.

Several other equities analysts have also issued reports on AXON. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $500.00 to $700.00 in a research report on Tuesday, December 3rd. JMP Securities raised their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Northland Securities raised their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, Robert W. Baird upped their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research note on Friday, December 6th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $504.92.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $577.34 on Wednesday. The firm has a fifty day simple moving average of $601.33 and a two-hundred day simple moving average of $445.99. Axon Enterprise has a twelve month low of $246.99 and a twelve month high of $698.67. The company has a market capitalization of $44.03 billion, a PE ratio of 149.18, a P/E/G ratio of 14.19 and a beta of 1.04. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. This trade represents a 3.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeffrey C. Kunins sold 21,834 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the completion of the transaction, the insider now owns 154,394 shares in the company, valued at approximately $91,691,508.72. This represents a 12.39 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,545 shares of company stock valued at $31,159,317. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Axon Enterprise

Institutional investors and hedge funds have recently modified their holdings of the business. Quent Capital LLC boosted its position in shares of Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC lifted its stake in Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 44 shares during the period. Brooklyn Investment Group purchased a new stake in shares of Axon Enterprise during the 3rd quarter valued at about $41,000. Planning Capital Management Corp lifted its position in Axon Enterprise by 83.3% during the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 55 shares during the period. Finally, Friedenthal Financial bought a new stake in Axon Enterprise in the 3rd quarter worth approximately $51,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.